Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

$50.22 0.53 (1.07 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$50.22
Today's Range$49.52 - $50.40
52-Week Range$37.26 - $65.51
Volume1.16 million shs
Average Volume859,738 shs
Market Capitalization$6.25 billion
P/E Ratio358.71
Dividend YieldN/A
Beta2.86

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:IONS
CUSIP46433010
Phone+1-760-9319200

Debt

Debt-to-Equity Ratio1.50%
Current Ratio6.25%
Quick Ratio6.21%

Price-To-Earnings

Trailing P/E Ratio358.714285714286
Forward P/E Ratio-358.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$346.62 million
Price / Sales18.08
Cash FlowN/A
Price / CashN/A
Book Value$0.82 per share
Price / Book61.24

Profitability

Trailing EPS$0.14
Net Income$-86,550,000.00
Net Margins-4.05%
Return on Equity-1.50%
Return on Assets-1.68%

Miscellaneous

Employees435
Outstanding Shares124,800,000

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.05. The company had revenue of $38.50 million for the quarter, compared to the consensus estimate of $38.52 million. Ionis Pharmaceuticals had a negative net margin of 4.05% and a negative return on equity of 1.50%. The firm's revenue for the quarter was down 68.0% compared to the same quarter last year. View Ionis Pharmaceuticals' Earnings History.

When will Ionis Pharmaceuticals make its next earnings announcement?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Ionis Pharmaceuticals.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2018?

13 equities research analysts have issued 1 year price targets for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $50.92 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

What are Wall Street analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (11/9/2017)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 72)
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance (Age 55)
  • B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director (Age 63)
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary (Age 43)
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research (Age 60)
  • Richard S. Geary Ph.D., Senior Vice President - Development (Age 59)
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development (Age 55)
  • Sarah Boyce, Chief Business Officer (Age 45)
  • Spencer R. Berthelsen M.D., Independent Director (Age 64)
  • Breaux B. Castleman, Independent Director (Age 76)

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.32%), Sicart Associates LLC (0.32%), Frontier Capital Management Co. LLC (0.05%), BLB&B Advisors LLC (0.05%), Bank of Montreal Can (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Bank of Montreal Can, BLB&B Advisors LLC and Gofen & Glossberg LLC IL. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Sicart Associates LLC and Fox Run Management L.L.C.. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $50.22.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $6.25 billion and generates $346.62 million in revenue each year. The company earns $-86,550,000.00 in net income (profit) each year or $0.14 on an earnings per share basis. Ionis Pharmaceuticals employs 435 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 Gazelle Ct, CARLSBAD, CA 92010-6670, United States. The company can be reached via phone at +1-760-9319200.


MarketBeat Community Rating for Ionis Pharmaceuticals (IONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  392 (Vote Outperform)
Underperform Votes:  400 (Vote Underperform)
Total Votes:  792
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ionis Pharmaceuticals (NASDAQ:IONS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.312.292.292.29
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.92$50.38$49.62$44.00
Price Target Upside: 6.90% downside7.87% downside18.90% downside19.58% downside

Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$64.00 -> $65.00N/AView Rating Details
11/8/2017Morgan StanleyBoost Price TargetEqual Weight$45.00 -> $49.00N/AView Rating Details
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingSell -> Sell$30.00N/AView Rating Details
9/21/2017BarclaysLower Price TargetEqual Weight$55.00 -> $52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$65.00LowView Rating Details
8/14/2017LaidlawReiterated RatingBuy$65.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingUnderperform$17.00 -> $18.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00HighView Rating Details
5/22/2017CowenReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings History and Estimates Chart

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.06)N/AView Earnings Details
8/8/2017Q2 2017($0.06)($0.09)$93.29 million$104.15 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.20)($0.13)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.25)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.17)($0.10)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.11)($0.16)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.05)($0.07)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.01)($0.03)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.04)$0.03ViewN/AView Earnings Details
2/25/2009Q4 2008($0.03)($0.06)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.05)$0.03ViewN/AView Earnings Details
8/7/2008Q2 2008($0.05)($0.02)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.11)($0.05)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.28)($0.04)($0.16)
Q2 20182($0.29)($0.03)($0.16)
Q3 20182($0.27)$0.00($0.14)
Q4 20182($0.25)$0.05($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 91.40%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Joseph Klein IIIDirectorSell3,000$50.56$151,680.0012,939View SEC Filing  
1/16/2018B Lynne ParshallDirectorSell5,986$51.76$309,835.3644,166View SEC Filing  
1/16/2018Brett P MoniaCOOSell2,821$51.76$146,014.9618,604View SEC Filing  
1/16/2018C Frank BennettSVPSell2,696$51.76$139,544.9621,810View SEC Filing  
1/16/2018Elizabeth L HougenCFOSell2,724$51.76$140,994.2417,224View SEC Filing  
1/16/2018Sarah BoyceInsiderSell2,196$51.76$113,664.9611,127View SEC Filing  
1/15/2018Stanley T CrookeChairmanSell16,549$51.76$856,576.2467,626View SEC Filing  
1/8/2018Stanley T CrookeChairmanSell11,000$52.01$572,110.0048,014View SEC Filing  
1/3/2018Stanley T CrookeChairmanSell22,000$50.01$1,100,220.0058,014View SEC Filing  
1/2/2018Brett P MoniaSVPSell163$50.00$8,150.0011,782View SEC Filing  
12/29/2017Joseph Klein IIIDirectorSell3,000$50.56$151,680.00View SEC Filing  
12/15/2017Elizabeth L HougenSVPSell5,000$52.55$262,750.0015,392View SEC Filing  
12/15/2017Joseph Klein IIIDirectorSell3,000$51.69$155,070.0012,939View SEC Filing  
12/4/2017Elizabeth L HougenSVPSell4,000$57.00$228,000.0014,392View SEC Filing  
12/1/2017Patrick R O'neilSVPSell1,000$55.50$55,500.0011,433View SEC Filing  
11/30/2017Joseph Klein IIIDirectorSell3,000$53.55$160,650.0012,939View SEC Filing  
11/29/2017Elizabeth L HougenSVPSell6,000$53.02$318,120.0016,392View SEC Filing  
11/16/2017Elizabeth L HougenSVPSell7,000$54.35$380,450.0017,392View SEC Filing  
11/15/2017Joseph Klein IIIDirectorSell2,250$53.56$120,510.009,377View SEC Filing  
11/13/2017Joseph Klein IIIDirectorSell3,000$55.39$166,170.007,127View SEC Filing  
11/1/2017Patrick R O'neilSVPSell1,000$58.35$58,350.0011,433View SEC Filing  
10/18/2017B Lynne ParshallCOOSell16,118$65.00$1,047,670.0033,526View SEC Filing  
10/18/2017C Frank BennettSVPSell12,250$65.00$796,250.0027,291View SEC Filing  
10/13/2017Richard S GearySVPSell8,268$60.00$496,080.00View SEC Filing  
10/13/2017Stanley T CrookeChairmanSell16,500$59.46$981,090.00View SEC Filing  
10/5/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
10/4/2017Stanley T CrookeChairmanSell27,500$52.89$1,454,475.00View SEC Filing  
10/2/2017Stanley T CrookeCEOSell15,000$52.00$780,000.0043,014View SEC Filing  
9/6/2017Patrick R O'neilSVPSell1,000$55.00$55,000.0010,633View SEC Filing  
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.0025,041View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.0048,014View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.0053,014View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.1511,935View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.0051,476View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.0010,369View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.5010,299View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.0053,014View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.0010,523View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.0043,014View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.0048,014View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.0010,449View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.0019,788View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.5030,276View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.0012,949View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.0012,449View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.3419,459View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.589,287View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.177,059View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.695,318View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.7830,576View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.0037,029View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.0030,029View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.408,181View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.407,872View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.0016,693View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.009,048View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.009,876View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.0023,693View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.009,720View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.009,048View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.0015,803View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.0035,029View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.0045,029View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.0045,029View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.0025,558View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.0015,043View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.0010,124View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.0030,029View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.0030,029View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.0010,124View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.3216,290View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.6010,590View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.546,331View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.121,735View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.4625,029View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.0014,642View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.458,215View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.004,358View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.0014,642View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.697,316View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.006,259View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.505,543View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.007,316View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.007,316View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.006,259View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.0014,642View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.008,143View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.006,941View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.904,022View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.582,313View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.0031,135View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.004,955View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.284,022View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.166,941View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.003,610View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.001,661View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.001,661View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01956View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00956View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.9841,135View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.002,866View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.0045,866View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00956View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01769View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.601,661View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.002,866View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22769View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.008,313View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ionis Pharmaceuticals (NASDAQ IONS) News Headlines

Source:
DateHeadline
Ionis Pharmaceuticals Inc (IONS) Expected to Announce Earnings of -$0.06 Per ShareIonis Pharmaceuticals Inc (IONS) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - January 20 at 5:24 AM
B Lynne Parshall Sells 5,986 Shares of Ionis Pharmaceuticals Inc (IONS) StockB Lynne Parshall Sells 5,986 Shares of Ionis Pharmaceuticals Inc (IONS) Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $856,576.24 in Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 2,696 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 2,696 Shares of Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Elizabeth L. Hougen Sells 2,724 Shares of Ionis Pharmaceuticals Inc (IONS) StockElizabeth L. Hougen Sells 2,724 Shares of Ionis Pharmaceuticals Inc (IONS) Stock
www.americanbankingnews.com - January 18 at 12:32 AM
Ionis Pharmaceuticals Inc (IONS) Insider Sarah Boyce Sells 2,196 SharesIonis Pharmaceuticals Inc (IONS) Insider Sarah Boyce Sells 2,196 Shares
www.americanbankingnews.com - January 18 at 12:32 AM
Will 2018 Be Ionis Pharmaceuticals, Inc.s Best Year Yet? - Nasdaq ... - NasdaqWill 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet? - Nasdaq ... - Nasdaq
www.nasdaq.com - January 15 at 3:34 PM
Ionis Pharmaceuticals Inc (IONS) Receives Consensus Recommendation of "Hold" from AnalystsIonis Pharmaceuticals Inc (IONS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 15 at 12:06 PM
Comparing Ionis Pharmaceuticals (IONS) & OHR Pharmaceutical (OHRP)Comparing Ionis Pharmaceuticals (IONS) & OHR Pharmaceutical (OHRP)
www.americanbankingnews.com - January 15 at 7:12 AM
Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS)Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS)
www.americanbankingnews.com - January 14 at 3:38 AM
OncoGenex Pharmaceuticals (ACHV) and Ionis Pharmaceuticals (IONS) Critical ComparisonOncoGenex Pharmaceuticals (ACHV) and Ionis Pharmaceuticals (IONS) Critical Comparison
www.americanbankingnews.com - January 13 at 5:06 PM
IONS March 2nd Options Begin TradingIONS March 2nd Options Begin Trading
www.nasdaq.com - January 11 at 11:49 AM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in Stock
www.americanbankingnews.com - January 10 at 9:38 PM
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
finance.yahoo.com - January 10 at 11:36 AM
Ionis Pharma (IONS) Says Inotersen NDA Accepted for Priority Review by FDA - StreetInsider.comIonis Pharma (IONS) Says Inotersen NDA Accepted for Priority Review by FDA - StreetInsider.com
www.streetinsider.com - January 8 at 3:38 PM
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options - NasdaqImplied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options - Nasdaq
www.nasdaq.com - January 6 at 3:34 PM
Ionis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in StockIonis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in Stock
www.americanbankingnews.com - January 5 at 6:16 PM
Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock OptionsImplied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options
finance.yahoo.com - January 5 at 10:52 AM
-$0.06 EPS Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter-$0.06 EPS Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter
www.americanbankingnews.com - January 3 at 8:18 AM
Ionis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 SharesIonis Pharmaceuticals Inc (IONS) Director Joseph Klein III Sells 3,000 Shares
www.americanbankingnews.com - January 2 at 7:32 PM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) Director Sells 3,000 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - January 2 at 7:32 PM
ETFs with exposure to Ionis Pharmaceuticals, Inc. : December 29, 2017ETFs with exposure to Ionis Pharmaceuticals, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:33 PM
Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017
finance.yahoo.com - December 28 at 10:22 AM
BidaskClub Lowers Ionis Pharmaceuticals (IONS) to HoldBidaskClub Lowers Ionis Pharmaceuticals (IONS) to Hold
www.americanbankingnews.com - December 22 at 7:32 PM
Ionis Pharma (IONS) Reports Initiation of Phase 1 Clinical Study of IONIS-JBI1-2.5Rx - StreetInsider.comIonis Pharma (IONS) Reports Initiation of Phase 1 Clinical Study of IONIS-JBI1-2.5Rx - StreetInsider.com
www.streetinsider.com - December 22 at 11:28 AM
Ionis Pharmaceuticals Inc (IONS) Given Consensus Rating of "Hold" by AnalystsIonis Pharmaceuticals Inc (IONS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 21 at 11:50 AM
Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal DisordersIonis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal Disorders
finance.yahoo.com - December 21 at 10:57 AM
Ionis Pharmaceuticals Inc (IONS) Director Sells $155,070.00 in StockIonis Pharmaceuticals Inc (IONS) Director Sells $155,070.00 in Stock
www.americanbankingnews.com - December 19 at 11:32 PM
Insider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 5,000 Shares of StockInsider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 5,000 Shares of Stock
www.americanbankingnews.com - December 19 at 11:32 PM
$115.44 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter$115.44 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter
www.americanbankingnews.com - December 19 at 5:54 AM
Ionis License Agreement for Huntingtons Disease Drug, IONIS-HTT Rx, Receives HSR Clearance - PR Newswire (press release)Ionis' License Agreement for Huntington's Disease Drug, IONIS-HTT Rx, Receives HSR Clearance - PR Newswire (press release)
www.prnewswire.com - December 18 at 11:08 AM
Ionis License Agreement for Huntingtons Disease Drug, IONIS-HTT Rx, Receives HSR ClearanceIonis' License Agreement for Huntington's Disease Drug, IONIS-HTT Rx, Receives HSR Clearance
finance.yahoo.com - December 18 at 11:08 AM
Traders Purchase High Volume of Ionis Pharmaceuticals Put Options (IONS)Traders Purchase High Volume of Ionis Pharmaceuticals Put Options (IONS)
www.americanbankingnews.com - December 17 at 1:34 AM
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus ... - GlobeNewswire (press release)Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 11:10 AM
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with ... - PR Newswire (press release)Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with ... - PR Newswire (press release)
www.prnewswire.com - December 12 at 3:35 PM
Analysts’ Recommendations for BioMarin in December 2017Analysts’ Recommendations for BioMarin in December 2017
finance.yahoo.com - December 12 at 11:22 AM
Ionis Pharma (IONS) Licenses IONIS-HTT Rx to Partner Roche Following Successful Phase 1/2a Study in Patients with ... - StreetInsider.comIonis Pharma (IONS) Licenses IONIS-HTT Rx to Partner Roche Following Successful Phase 1/2a Study in Patients with ... - StreetInsider.com
www.streetinsider.com - December 11 at 11:35 AM
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntingtons DiseaseIonis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
finance.yahoo.com - December 11 at 11:35 AM
Ground-breaking new drug gives hope in Huntingtons disease'Ground-breaking' new drug gives hope in Huntington's disease
finance.yahoo.com - December 11 at 11:35 AM
Ionis Pharmaceuticals (IONS) Upgraded at BidaskClubIonis Pharmaceuticals (IONS) Upgraded at BidaskClub
www.americanbankingnews.com - December 7 at 11:52 PM
Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference - PR Newswire (press release)Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - December 7 at 3:37 PM
Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 4,000 Shares of StockInsider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 4,000 Shares of Stock
www.americanbankingnews.com - December 6 at 8:52 PM
Today’s Research Reports on Stocks to Watch: Ionis Pharmaceuticals and GW PharmaceuticalsToday’s Research Reports on Stocks to Watch: Ionis Pharmaceuticals and GW Pharmaceuticals
finance.yahoo.com - December 5 at 11:29 AM
Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : December 4, 2017Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : December 4, 2017
finance.yahoo.com - December 4 at 11:11 AM
Patrick R. Oneil Sells 1,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) StockPatrick R. O'neil Sells 1,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - December 1 at 10:50 PM
Ionis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 3,000 SharesIonis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 3,000 Shares
www.americanbankingnews.com - December 1 at 9:50 PM
Elizabeth L. Hougen Sells 6,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) StockElizabeth L. Hougen Sells 6,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - December 1 at 9:28 PM
Zacks: Analysts Anticipate Ionis Pharmaceuticals, Inc. (IONS) Will Post Quarterly Sales of $115.44 MillionZacks: Analysts Anticipate Ionis Pharmaceuticals, Inc. (IONS) Will Post Quarterly Sales of $115.44 Million
www.americanbankingnews.com - December 1 at 7:49 AM
-$0.06 Earnings Per Share Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter-$0.06 Earnings Per Share Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter
www.americanbankingnews.com - November 29 at 9:12 AM

SEC Filings

Ionis Pharmaceuticals (NASDAQ:IONS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ionis Pharmaceuticals (NASDAQ:IONS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ionis Pharmaceuticals (NASDAQ IONS) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.